Amylyx Pharma将终止患有进行性核上性麻痹的成年人的ORION AMX 0035计划

- AMX0035 did not show differences compared to placebo on primary or secondary outcomes at Week 24

- AMX0035 continued to be generally well-tolerated

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) ("Amylyx" or the "Company") today announced the decision to discontinue the ORION program of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO, also known as ursodoxicoltaurine]) in adults living with progressive supranuclear palsy (PSP).

AMX0035 did not show differences compared to placebo on primary or secondary outcomes at Week 24. Based on these results, the Company will discontinue the Phase 2b trial and open-label extension and will not initiate the Phase 3 portion of the program. Safety data were consistent with safety data from prior studies, and AMX0035 continued to be generally well-tolerated.